Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OAsIs: Obinutuzumab + Venetoclax + Ibrutinib in Mantle Cell Lymphoma
2024-516750-21-00Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Oct 2015
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of obinutuzumab, venetoclax and ibrutinib in mantle cell lymphoma (MCL) (3 arms), sponsored by CHU de Nantes. Primary endpoints: Unacceptable toxicity of GA101 + Ibrutinib (Step A), Dose-limiting toxicities of GA101 + Ibrutinib + GDC-0199 (Step B) and 1 more. Started Oct 2015; status: completed.
02
Drugs
obinutuzumabvenetoclaxibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2024-516750-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516750-21-00.